Retatrutide Results: The Trial Average Nobody's Posting

Twenty-four percent is the number that matters, and it comes from 338 people in a blinded trial, not from a single account seven weeks into a self-administered course.^[1] That gap, between an averaged, blinded, placebo-controlled result and one uncontrolled report, is the entire story behind every “retatrutide results” thread making the rounds right now. The trial data are honest about what they measured. Most of what gets posted alongside them isn’t measuring anything at all.

What the phase 2 trials measured

The headline figure comes from one study: a 48-week, randomized, double-blind, placebo-controlled phase 2 trial that enrolled 338 adults with obesity and tested retatrutide doses up to 12 mg a week against placebo.^[1] It is the only dataset strong enough to carry the weight the internet puts on it.

24.2% mean weight loss at 48 weeks on the 12 mg dose, versus 2.1% on placebo PMID 37366315

The effect was still climbing when the trial ended. At 24 weeks, the 12 mg group had lost a mean of 17.5% of body weight. By week 48, that number had grown to 24.2%.^[1] A curve that is still rising at the final measurement point means the 48-week number is a snapshot of an unfinished process. It isn’t a ceiling.

A second, separate phase 2 trial tested the same molecule in adults with type 2 diabetes, and it reported a smaller result: a mean weight loss of about 17% on the 12 mg dose at 36 weeks, against 3% on placebo.^[2] Same drug, different population, meaningfully different number.

Two separate retatrutide trials, two different results

Highest tested dose in each trial.

That gap matters for anyone reading a single number off a chart and assuming it applies to them. People with type 2 diabetes lost substantially less weight on the identical dose than people in the obesity-only trial did.^[2] Diabetes changes the math. A screenshot of “24%” strips that context out.

Why the trial average and a Reddit post are not the same evidence

The 24.2% figure survives scrutiny because of how the trial was designed. Neither participants nor investigators knew who was getting retatrutide and who was getting placebo.^[1] That blinding is what keeps a result from becoming a story people tell themselves.

A post describing fast weight change over a few weeks carries none of that protection. It cannot be separated from water-weight shifts, selective posting, or a dose nobody independently checked. Compare the two data sources directly:

• The trial: 338 people, randomized, blinded, placebo-controlled, measured on a fixed schedule for 48 weeks.
• The post: one person, no control group, no blinding, no verification of what was in the syringe.

What no published study has checked: whether compounded retatrutide bought outside a clinical trial contains the dose the label claims, or how pure it is. That question has no answer in the literature, which means every anecdote built on a compounded product is missing a variable the trial never had to worry about.

One report is one point. The trial average is the cluster.

This is the same reason a single testimonial never substitutes for a cohort in any area of medicine. The individual case can be true and still be uninformative about what to expect.

How fast the trial results appeared

Nobody in the obesity trial started at 12 mg. Participants assigned to the higher target doses began at a lower initial dose and were escalated over time, so the 24.2% figure describes a full year of treatment. It is not a few-week result.^[1] Our breakdown of the dosing ladder covers exactly how that escalation was structured and why it isn’t a protocol to copy.

The published data report weight change at fixed checkpoints, 24 weeks and 48 weeks. There is no continuous week-by-week curve in the public record, so an individual’s path between those points simply isn’t there.

No published retatrutide trial has reported results at the early timepoints, seven weeks in particular, that some individual posts describe. Whatever is happening in those early-week reports, it isn’t something the trial measured and it isn’t something the trial can confirm or deny.

What the eloralintide comparison claim leaves out

A separate compound, eloralintide, is drawing comparisons online, with claims that it has “dethroned” retatrutide. Eloralintide is a selective amylin-receptor agonist, mechanistically distinct from retatrutide’s triple action on the GIP, GLP-1, and glucagon receptors, and it has been studied in its own right: a 48-week phase 2 trial of 263 participants with obesity, with percent change in bodyweight as the primary endpoint.^[3]

Two drugs, two separate trials, no head-to-head

Each result comes from its own placebo-controlled trial.

No published human trial has put retatrutide and a tirzepatide-eloralintide combination head to head. A claim that one investigational treatment has outperformed another needs a trial that randomizes people to both and compares them directly. That trial doesn’t exist yet, so the claim is a guess dressed up as a result.

The same skepticism applies to any cross-trial comparison that stacks numbers from different trial designs on top of each other. Our look at semaglutide, tirzepatide, and retatrutide runs into the identical problem: different enrollment criteria, different durations, different placebo responses, all collapsed into one ranked list online as if they were measured side by side.

Amylin biology is a useful contrast here. Retatrutide’s glucagon component is thought to add extra energy expenditure on top of appetite suppression, a mechanism unique among the drugs in this class. Amylin receptor agonists like eloralintide work mainly by slowing gastric emptying and promoting satiety through a different signaling pathway entirely, closer in spirit to how the older drug pramlintide was first used to blunt post-meal glucose spikes.

Two drugs that look similar on a weight-loss chart can be doing almost nothing alike inside the body. Only a head-to-head trial could settle which one works better for a given person, and a forum consensus is no substitute for one.

What the trial results do not establish

The published retatrutide trials report weight change only through the active treatment period, without a described follow-up period after participants stopped the drug.^[1] There is no published answer to what happens to that 24.2% once the injections stop.

A few more limits are worth stating plainly rather than letting them get smoothed over:

• Population: the trials enrolled adults with obesity or type 2 diabetes, not people at a healthy weight chasing a cosmetic result. The measured effect size may not transfer.
• Long-term safety: a 2024 review of hormone-based anti-obesity medications notes, specifically about retatrutide’s 48-week phase 2 results, that long-term data on this drug’s safety and cardiovascular benefits has not yet been established.^[4]
• Causation at the individual level: a single online report can show that a weight change was reported alongside retatrutide use. It cannot show that the drug caused it.

Our article on the trial’s reported side effects covers the adverse-event side of that same 48-week window in more detail.

Bottom line on durability and safety: the trials measured a dose-dependent weight-loss effect while people were on the drug, for up to a year. What happens after that, and what the drug does over a longer horizon, remains unanswered in the published record.

What this means if you’re trying to decide what to do

The honest summary of the evidence is a dose-dependent average weight loss approaching a quarter of body weight over roughly a year on the highest tested dose, with real variation around that average rather than a guarantee of it.^[1] That’s a genuinely large effect by the standards of obesity pharmacotherapy. It is also not what a single transformation photo represents.

A photo posted after a few weeks is one unverified case. It is not the distribution of outcomes the trial measured, and it was never designed to be. Some people in that trial lost far more than 24.2%, some lost far less, and the average sits in between those two groups rather than describing either one.

Anyone taking a compound whose dose and purity nobody has verified outside a monitored trial is accepting risks the trial itself never had to characterize, because the trial controlled for exactly that. The number worth repeating is 24.2%. The screenshot sitting next to it is worth nothing at all.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.